Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 271.00
Bid: 268.00
Ask: 271.00
Change: -5.50 (-1.99%)
Spread: 3.00 (1.119%)
Open: 272.00
High: 276.00
Low: 267.50
Prev. Close: 276.50
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Post-close trading update

18 Jul 2023 07:00

RNS Number : 2923G
Synthomer PLC
18 July 2023
 

Synthomer plcPost-close trading update

 

Synthomer plc ('Synthomer' or 'the Group') today announces an update regarding trading for the six months ended 30 June 2023 (the 'period') and our outlook for the remainder of 2023.

 

Group trading

Continuing Group revenue in the period was £1.1bn with EBITDA expected to be in the range of £72-74m, broadly consistent with the Board's expectations described in our 2022 results announcement in March. Continuing Group EBITDA in the second quarter was higher than the first, notwithstanding the challenging macroeconomic conditions throughout the period. Robust pricing and our strong focus on margins helped to mitigate substantially lower volumes compared with the first half of 2022, a consequence of destocking, subdued levels of demand across most of our end markets and increased competition in some of our base chemical product ranges.

 

We continued to focus on cash generation during the period, with reductions in capital expenditure, working capital and costs across the Group. As at 30 June 2023, net debt was c.£795m, with net debt:EBITDA on a leverage covenant basis of 5.5 times and committed liquidity of more than £400m.

 

Divisional update

All divisions continued to make progress against their key priorities, including delivery of our refreshed strategy as announced last October. Those parts of our portfolio identified as the more speciality, higher growth areas in our strategy review proved the most resilient during the period and are already beginning to benefit from our differentiated focus and investment.

 

Coatings & Construction Solutions (CCS) is achieving robust pricing and margins, with improved trading performance over the period compared with the last quarter of 2022 despite cautious customer buying behaviour. In line with our strategy, CCS recently implemented several actions to broaden geographic and customer penetration which will strengthen organic growth and increase market share over time, while enhancing margins.

 

The performance of Adhesive Solutions (AS) in the period continues to reflect the lower volume environment as well as the previously disclosed operational reliability and supply chain challenges in the adhesive resins business, acquired in early 2022. We expect our reliability and performance improvement measures to have a positive impact in the second half of the year, despite continued demand weakness. We also recently committed to expand our speciality amorphous polyolefins capacity in North America to support growth in this region.

 

In Heath & Protection and Performance Materials (HPPM), the challenging medical glove market dynamics which followed the unprecedented activity during the pandemic continue. In line with previous indications, we do not expect low nitrile butadiene rubber (NBR) production levels to abate before the end of 2023. We continue to focus on capacity management and cost control.

 

Our non-core portfolio rationalisation programme continued to progress during the period.

 

Update on outlook

The Board does not anticipate a material recovery in customer demand before the end of the current year. However, we anticipate c.£20m in self-help measures expected mainly in H2. Overall the Group remains confident of making sequential progress in the second half relative to the first.

 

The Group continues to take decisive action to strengthen our business so that it is positioned for profitable growth when demand does begin to recover. We remain confident in our ability to execute our refreshed strategy and deliver the medium-term targets set out last October, which were mid-single-digit growth in constant currency over the cycle, EBITDA margins above 15% and mid-teens return on invested capital.

 

Synthomer will report half year results for the six months to 30 June on 7 September 2023.

 

 

Further information:

Investors: Faisal Tabbah, Vice President Investor Relations Tel: +44 (0) 1279 775 306

Media: Charles Armitstead, Teneo Tel: +44 (0) 7703 330 269

 

Notes

Legal Entity Identifier (LEI): 213800EHT3TI1KPQQJ56. Classification as per DTR 6 Annex 1R: 3.1.

 

Synthomer plc is a leading supplier of high-performance, specialty polymers and ingredients for coatings, construction, adhesives, and healthcare end markets. Headquartered in London, UK and listed there since 1971, we employ around 4,400 employees across nearly 40 locations across Europe, USA and Asia. With more than 6,000 customers and £2.4bn in continuing revenue in 2022, our three divisions are aligned to our end markets which play an important role in global megatrends including urbanisation, climate change, and economic and demographic shifts. In Coatings & Construction Solutions, our tailored solutions enhance the sustainability and performance of a range of products such as architectural and masonry coatings, mortar modification, fibre bonding, waterproofing and flooring, while our energy solutions promote drilling stability in the challenging operating environments of the oil and gas industry. Adhesive Solutions is a leading supplier of products that bond, modify and compatibilise surfaces and components for a range of end markets including tapes and labels, packaging, hygiene, tyres and plastics. In Health & Protection and Performance Materials we are a world-leading supplier of water-based polymers for medical gloves and a major European manufacturer of high-performance binders, foams and other products for a range of niche applications. Our purpose is creating innovative and sustainable solutions for the benefit of customers and society. Around 20% of our sales volumes are from new and patent protected products. At our innovation hubs in the UK, Germany, Malaysia and Ohio, USA we collaborate closely with our customers to develop new products tailored to their needs while also minimising environmental impact. We are working to embed sustainability in everything we do; we have reduced our scope 1 and 2 carbon footprint by one third since 2019, and our 2030 decarbonisation targets have been approved by the Science Based Targets initiative as being in line with what the latest climate science says is necessary to meet the goals of the Paris Agreement. Since 2021 we have held the London Stock Exchange Green Economy Mark, which recognises green technology businesses making a significant contribution to a more sustainable, low-carbon economy. Find us at www.synthomer.com, @Synthomer_Group on Twitter or search for Synthomer on LinkedIn.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTGPUCGMUPWGBM
Date   Source Headline
12th Mar 20071:00 pmRNSDirector/PDMR Shareholding
7th Mar 20077:01 amRNSFinal Results
6th Mar 20074:04 pmRNSHolding(s) in Company
20th Feb 20074:29 pmRNSNotice of Results
1st Feb 20074:23 pmRNSBlocklisting Interim Review
18th Dec 20062:08 pmRNSVoting Rights and Capital
15th Dec 20067:58 amRNSTrading Statement
4th Dec 200612:49 pmRNSBlocklisting Interim Review
12th Oct 200610:46 amRNSHolding(s) in Company
2nd Oct 20063:20 pmRNSDirector/PDMR Shareholding
8th Sep 20069:01 amRNSDirector/PDMR Shareholding
7th Sep 20067:01 amRNSInterim Results
21st Aug 20063:22 pmRNSNotice of Results
21st Aug 20062:41 pmRNSDirectorate Change
1st Aug 20062:51 pmRNSBlocklisting Interim Review
14th Jul 20063:51 pmRNSNew Chief Executive
7th Jun 200611:14 amRNSDirector/PDMR Shareholding
5th Jun 20067:00 amRNSDisposal of Reabrook Limited
1st Jun 20064:48 pmRNSBlocklisting Interim Review
25th May 20063:11 pmRNSDirector/PDMR Shareholding
25th May 20063:09 pmRNSDirector/PDMR Shareholding
18th May 20064:59 pmRNSResult of AGM
18th May 200612:00 pmRNSAGM Statement
3rd May 200612:28 pmRNSAnnual Information Update
18th Apr 20063:49 pmRNSAnnual Report and Accounts
13th Apr 200611:30 amRNSDirector/PDMR Shareholding
13th Apr 200611:28 amRNSDirector/PDMR Shareholding
21st Mar 200612:05 pmRNSDirector/PDMR Shareholding
16th Mar 20067:01 amRNSFinal Results
20th Feb 20063:44 pmRNSHolding(s) in Company
20th Feb 20062:00 pmRNSAppointment
9th Feb 200612:10 pmRNSNotice of Results
31st Jan 200610:00 amRNSAdditional Listing
30th Dec 200512:00 pmRNSWithdrawal from SO2 business
23rd Dec 200510:14 amRNSDirector/PDMR Shareholding
14th Dec 20057:00 amRNSPre-close Trading Statement
8th Dec 20051:29 pmRNSBlocklisting Interim Review
7th Dec 20058:42 amRNSSale of Autoclenz Limited
7th Dec 20057:01 amRNSAdmission to trading on AIM
6th Dec 20054:23 pmRNSDirector Declaration
6th Dec 20054:18 pmRNSDirectorate Change
2nd Dec 200510:07 amRNSSale of Autoclenz Limited
15th Nov 20054:54 pmRNSHolding(s) in Company
31st Oct 20059:45 amRNSProposed sale - Autoclenz Ltd
5th Oct 20052:36 pmRNSDirector/PDMR Shareholding
29th Sep 200512:08 pmRNSDirector/PDMR Shareholding
14th Sep 20053:02 pmRNSHolding(s) in Company
17th Aug 20059:50 amRNSNotice of Results
13th Jul 20053:46 pmRNSChief Operating Officer
1st Jul 200511:15 amRNSJames Robinson Consolidation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.